A. Rogel, F. Hamers, C. Quintin, D. Maria, F. Bonaldi et al.,

, Incidence et dépistage du cancer du sein en France. Dernières données disponibles : octobre 2016, 2016.

B. Séradour, H. Allemand, A. Weill, and P. Ricordeau, Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from, Bull. Cancer (Paris), vol.96, pp.1-6, 2000.

C. I. Li, J. R. Daling, and K. E. Malone, Age-specific incidence rates of in situ breast carcinomas by histologic type, Cancer Epidemiol. Biomark. Prev. Publ, 1980.

, Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol, vol.14, pp.1008-1019, 2005.

B. A. Virnig, T. Shamliyan, T. M. Tuttle, R. L. Kane, and T. J. Wilt, Diagnosis and Management of Ductal Carcinoma in Situ (DCIS)

, Agency for Healthcare Research and Quality

, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC, 2003.

C. K. Kuhl, Why do purely intraductal cancers enhance on breast MR images?, Radiology, vol.253, pp.281-284, 2009.

S. A. Jansen, T. Paunesku, X. Fan, G. E. Woloschak, S. Vogt et al.,

, Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrastenhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model, Radiology, vol.253, pp.399-406, 2009.

A. J. Guidi, S. J. Schnitt, L. Fischer, K. Tognazzi, J. R. Harris et al.,

, Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast, Cancer, vol.80, pp.1945-53, 1997.

C. K. Kuhl, S. Schrading, H. B. Bieling, E. Wardelmann, C. C. Leutner et al.,

, MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study, The Lancet, vol.370, pp.485-92, 2007.

M. Iima, K. Yano, M. Kataoka, M. Umehana, K. Murata et al.,

, Quantitative non-Gaussian diffusion and intravoxel incoherent motion magnetic resonance imaging: differentiation of malignant and benign breast lesions, Invest. Radiol, vol.50, pp.205-216, 2015.

M. Iima, L. Bihan, D. Okumura, R. Okada, T. Fujimoto et al.,

, Apparent diffusion coefficient as an MR imaging biomarker of low-risk ductal carcinoma in situ: a pilot study, Radiology, vol.260, pp.364-72, 2011.

L. R. Allen, C. E. Lago-toro, J. H. Hughes, E. Careaga, A. T. Brown et al.,

, Is there a role for MRI in the preoperative assessment of patients with DCIS?

, Surg. Oncol, vol.17, pp.2395-400, 2010.

A. P. Schouten-van-der-velden, M. S. Schlooz-vries, C. Boetes, and T. Wobbes,

, Magnetic resonance imaging of ductal carcinoma in situ: what is its clinical application? A review, Am. J. Surg, vol.198, pp.262-271, 2009.

P. P. Rosen, D. W. Braun, and D. E. Kinne, The clinical significance of pre-invasive breast carcinoma, Cancer, vol.46, pp.919-944, 1980.

M. E. Sanders, P. A. Schuyler, W. D. Dupont, and D. L. Page, The natural history of lowgrade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up, Cancer, vol.103, pp.2481-2485, 2005.

E. J. Groen, L. E. Elshof, L. L. Visser, E. Rutgers, . Winter-warnars et al., Finding the balance between over-and under-treatment of ductal carcinoma in situ (DCIS), Breast Edinb. Scotl, vol.31, pp.274-83, 2017.

, Cancers du sein -Recommandations et outils d'aide à la pratique

, Lagios MD. Heterogeneity of duct carcinoma in situ (DCIS): Relationship of grade and subtype analysis to local recurrence and risk of invasive transformation, Cancer Lett, vol.90, pp.97-102, 1995.

J. H. Menell, E. A. Morris, D. D. Dershaw, A. F. Abramson, E. Brogi et al.,

, Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging, Breast J, vol.11, pp.382-90, 2005.

W. A. Berg, L. Gutierrez, M. S. Nessaiver, W. B. Carter, M. Bhargavan et al.,

, Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer, Radiology, vol.233, pp.830-879, 2004.

G. H. Sakorafas and A. G. Tsiotou, Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives, Cancer Treat. Rev, vol.26, pp.103-128, 2000.

/. Systems and . Bi, , 2018.

S. A. Jansen, A. Scott-moncrieff, M. E. Sullivan, E. B. Mendelson, and L. Wang, Ductal carcinoma in situ: detection, diagnosis, and characterization with magnetic resonance imaging, Semin. Ultrasound. CT MR, vol.32, pp.343-352, 2011.

H. I. Greenwood, S. L. Heller, S. Kim, E. E. Sigmund, S. D. Shaylor et al., Ductal Carcinoma in Situ of the Breasts: Review of MR Imaging Features, RadioGraphics, vol.33, pp.1569-88, 2013.

S. H. Baek, W. J. Choi, J. H. Cha, H. H. Kim, H. J. Shin et al., Comparison of mammography, ultrasound, and MRI in size assessment of ductal carcinoma in situ with histopathologic correlation, Acta Radiol. Stockh. Swed, vol.58, pp.1434-1475, 1987.

W. Zhou, K. Jirström, R. Amini, M. Fjällskog, S. T. Lindman et al.,

, Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study, BMC Cancer, vol.13, p.512, 2013.

S. A. Jansen, G. M. Newstead, H. Abe, A. Shimauchi, R. A. Schmidt et al.,

, Pure Ductal Carcinoma in Situ: Kinetic and Morphologic MR Characteristics Compared with Mammographic Appearance and Nuclear Grade, Radiology, vol.245, pp.684-91, 2007.

I. Thomassin-naggara, C. Salem, E. Darai, M. Bazot, S. Uzan et al.,

, sénologie -Le rehaussement sans masse en IRM mammaire : comment j'interprète ?, J. Radiol, vol.90, pp.269-75, 2009.

M. Goto, H. Ito, K. Akazawa, T. Kubota, O. Kizu et al., Diagnosis of breast tumors by contrast-enhanced MR imaging: comparison between the diagnostic performance of dynamic enhancement patterns and morphologic features, J. Magn. Reson. Imaging JMRI, vol.25, pp.104-116, 2007.

E. Furman-haran, E. Schechtman, F. Kelcz, K. Kirshenbaum, and H. Degani, Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions, Cancer, vol.104, pp.708-726, 2005.

D. A. Bluemke, C. A. Gatsonis, M. H. Chen, G. A. Deangelis, N. Debruhl et al.,

, Magnetic resonance imaging of the breast prior to biopsy, JAMA, vol.292, pp.2735-2777, 2004.

C. D. Lehman, Magnetic Resonance Imaging in the Evaluation of Ductal Carcinoma In Situ, J. Natl. Cancer Inst. Monogr, vol.2010, pp.150-151, 2010.

S. Kul, A. Cansu, E. Alhan, H. Dinc, G. Gunes et al., Contribution of diffusionweighted imaging to dynamic contrast-enhanced MRI in the characterization of breast tumors, AJR Am. J. Roentgenol, vol.196, pp.210-217, 2011.

A. P. Schouten-van-der-velden, C. Boetes, P. Bult, and T. Wobbes, The value of magnetic resonance imaging in diagnosis and size assessment of in situ and small invasive breast carcinoma, Am. J. Surg, vol.192, pp.172-180, 2006.

M. Kriege, C. Brekelmans, C. Boetes, P. E. Besnard, H. M. Zonderland et al.,

. Im, Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition, N. Engl. J. Med, vol.351, pp.427-464, 2004.

W. Wu, H. Kamma, E. Ueno, M. Fujiwara, H. Satoh et al., The intraductal component of breast cancer is poorly responsive to neo-adjuvant chemotherapy, Oncol. Rep, vol.9, pp.1027-1058, 2002.

H. Goldberg, J. Zandbank, V. Kent, M. Leonov-polak, A. Livoff et al., Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications, Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol, vol.43, pp.1415-1435, 2017.

J. J. Noguera, E. De-luis, A. , A. Viteri, S. Zornoza et al.,

G. Von-minckwitz, D. , S. Loibl, S. Huober, J. Tesch et al.,

, Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40), Breast Cancer Res. Treat, vol.132, pp.863-70, 2012.

S. R. Gunia, M. S. Patel, and E. P. Mamounas, Pathologic Complete Response of HER-2

. Neu-positive, Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature. Case Rep, Surg, p.454273, 2012.

G. Curigliano, H. J. Burstein, E. P. Winer, M. Gnant, P. Dubsky et al., Deescalating and escalating treatments for early-stage breast cancer: the St, Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer, vol.28, pp.1700-1712, 2017.

, Serment d'Hippocrate

, Au moment d'être admis à exercer la médecine, en présence des maîtres de cette école et de mes condisciples, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité qui la régissent

, Mon premier souci sera, de rétablir, de préserver ou de promouvoir la santé dans tous les éléments physiques et mentaux, individuels collectifs et sociaux. Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur

, J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou dignité

, Même sous la contrainte, je ne ferai usage de mes connaissances contre les lois de l'humanité

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer leurs consciences

, Je donnerai mes soins à l'indigent et à quiconque me les demandera

, Je ne me laisserai influencer ni par la recherche du gain ni par la recherche de la gloire

, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers. Et ma conduite ne servira pas à corrompre les moeurs

, Je ferai tout pour soulager les souffrances, sans acharnement

, Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission

, Je n'entreprendrai rien qui ne dépasse mes compétences ; je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses, Que je sois déshonoré et méprisé si j'y manque